In CML, three tyrosine kinase inhibitors (TKI, dasatinib, imatinib, and nilotinib) are registered and recommended by expert groups for first-line treatment in CML. Furthermore, the scientific background of the formation, conditioning and disposal of high radioactive waste will be illustrated.ĭisclosure: No conflict of interest disclosed.įortbildung – Management der chronischen myeloischen Leukämie V15 – Therapy goals for first-line treatment in CML and implications for the doctorġMedizinische Fakultät Mannheim der Universität Heidelberg, III. Where are the potential sites in Germany located?Īre there any alternatives to a disposal in deep geological formations?Īll these questions will be discussed within the talk “Nuclear waste disposal – what do we pass to our children?”. Which kind of criteria are of importance for the site selection process? With the final report a new chapter in the field of searching and building a nuclear waste repository in Germany will be opened.
The commission of the German Parliament which deals with the law for the site selection will finish their work until this year. Abstracts Plenarsitzung – Eröffnungsveranstaltung V14 – Nuclear waste disposal – what do we pass to our children?ġInstitut für Ressourcenökologie / HZDR, Dresden, Germany
